- 1 Low-dose chemotherapy combined with delayed immunotherapy in the
- 2 neoadjuvant treatment of non-small cell lung cancer and dynamic monitoring of
- 3 the drug response in peripheral blood
- 4 Chaoyang Liang^{1†}, Qi Song^{2†}, Wenhao Zhou^{3†}, Na Li^{3†}, Qi Xiong², Chaohu Pan³,
- 5 Shaohong Zhao⁴, Xiang Yan², Xiaoling Zhang², Yaping Long⁵, Juntang Guo¹, Tao
- 6 Wang¹, Weiwei Shi², Shengjie Sun², Bo Yang¹, Zhouhuan Dong⁶, Haitao Luo^{3*}, Jie
- 7 Li^{6*}, Yi Hu^{2*}, and Bo Yang^{2*}
- ¹Department of Thoracic Surgery, the First Medical Center, Chinese PLA General
- 10 Hospital, Beijing, China.

- ²Department of Oncology, Chinese PLA General Hospital, Beijing, China.
- ³Shenzhen Engineering Center for Translational Medicine of Precision Cancer
- 13 Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, China.
- ⁴Department of Radiology, the First Medical Center, Chinese PLA General Hospital,
- 15 Beijing, China.
- 16 ⁵School of Medicine, Nankai University, Tianjin, China.
- ⁶Department of Pathology, the First Medical Center, Chinese PLA General Hospital,
- 18 Beijing, China.
- [†]Chaoyang Liang, Qi Song, Wenhao Zhou, and Na Li contributed equally to this
- 21 work.

19

22

- 23 ** Correspondence
- 24 Bo Yang: yangbo@301hospital.com.cn
- 25 Yi Hu: huyi@301hosptial.com.cn
- 26 Jie Li: lijiek812@301hospital.com.cn
- 27 Haitao Luo: luohhaitao@yucebio.com

29 **Abstract** 30 **Background:** Despite chemo-immunotherapy has been applied to the neoadjuvant 31 treatment of non-small cell lung cancer (NSCLC), the impacts of dosage and the order 32 of medication on treatment efficacy and safety remain largely unexplored. We 33 originally designed an exploratory study to investigate the efficacy and safety of 34 reduced-dose chemotherapy combined with delayed immunotherapy as well as the 35 dynamic changes of circulating tumor DNA (ctDNA) and T cell receptor (TCR) 36 during the therapy. 37 **Methods:** Patients with clinical stage IIA to IIIA resectable NSCLC were treated with 38 2 cycles of reduced-dose platinum-based chemotherapy on day 1 combined with immunotherapy on day 5. The same postoperative modified adjuvant therapy regimen 39 40 was administered for 2 cycles. Plasma samples at different time-points were collected 41 and performed with T cell receptor (TCR) and circulating tumor DNA (ctDNA) 42 sequencing. 43 **Results:** 38 patients received modified chemo-immunotherapy. The proportion of 44 patients exhibiting complete response and partial response was 5.3% and 68.4%, 45 respectively. The confirmed objective response rate was 73.7%. Radiological 46 downstaging was achieved in 39.5%. Major pathologic response and complete 47 pathologic response were observed in 47.4% and 31.6% of patients, respectively. 48 Only one patient experienced grade 3 adverse event. Further analyses revealed that 49 this modified chemo-immunotherapy led to the expansion of predominant TCR clones 50 and reduction of tumor burden after the first cycle of chemotherapy. 51 Conclusion: The promising clinical efficacy and low side effects of modified 52 neoadjuvant chemo-immunotherapy position it as a prospective and innovative 53 strategy for NSCLC. 54 Funding: This study was funded by the National Natural Science Fund of the 55 People's Republic of China (NSFC; No.81902912). 56

Trial registration: Registration Number: ChiCTR2000033092

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

Keywords: Non-small cell lung cancer, Modified neoadjuvant chemo-immunotherapy, Low-dose chemotherapy, Delayed immunotherapy, Treatment efficacy, Side effects, Circulating tumor DNA, T cell receptor **Background** Approximately 20 to 25% of patients diagnosed with NSCLC are eligible for surgical resection (1), yet 30% to 55% of those who undergo curative surgery will encounter recurrence and ultimately die (2, 3). Despite the improvement in treatment of NSCLC patients, the 5-year survival rates remain relatively low, hovering around 36% (4). Over the past decade, neoadjuvant platinum-based chemotherapy, followed by surgery, has become the standard of care. Nevertheless, only 5 to 6 % improvements have been noted in 5-year recurrence-free survival and overall survival rates compared to surgery alone (5). Currently, combination of chemotherapy with immunotherapy has demonstrated superior clinical efficacy and prolonged event-free survival for patients with resectable NSCLC. Trials such as CheckMate 816 (6), SAKK 16/14 (7), and NADIM (8), have showcased the enhanced efficacy and manageable safety of combination therapy compared to monotherapy. However, for most previous clinical trials, cytotoxic drugs with standard doses and anti-PD1 antibody were administrated on the same day (9), which may result in unsatisfactory eradication rates and relatively high incidence of severe treatment-related adverse events (TRAEs). To improve the cure rate and reduce TRAEs, the use of low-dose chemotherapy may represent a feasible alternative, given it favorable tolerability profile without compromising efficacy (10, 11). Although various regimens of low-dose chemotherapy have been utilized in cancer therapy (12, 13), the effects of dosage and administration sequence on the efficacy and safety of NSCLC treatment remain controversial. According to our previous research findings, the administration of immunotherapy 3-5 days after

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

chemotherapy significantly reduces lymphocyte damage (14). Therefore, we hypothesize that by coordinating the dosage of chemotherapy and the timing of immunotherapy administration, we can enhance the synergistic effects between the two interventions. Ultimately, this could improve clinical efficacy while reducing toxic side effects. To monitor the therapeutic efficacy during the process of chemo-immunotherapy, there is an urgent requirement for reliable indicators. The T cell receptor (TCR) repertoire and the presence of circulating tumor DNA (ctDNA) in blood have been proven to be efficient predictors of therapeutic responses in cancer treatment (15, 16). Chemotherapeutic agents have the capability to induce immunogenic death of tumor cells, reduce tumor burden, and promote the infiltration of CD8 T lymphocyte (17, 18). The recognition of tumor antigens by CD8 T lymphocytes relies primarily on the presence of a diverse and polymorphic TCR within an individual (19). Hence, it is imperative to explore the dynamic changes of TCR diversity and tumor burden in ctDNA throughout the course of therapy. In this study, we report the results of our pilot clinical trial assessing the efficacy and safety of modified neoadjuvant chemo-immunotherapy in patients with resectable NSCLC. These results indicate that the combination of low-dose chemotherapy followed by delayed immunotherapy could potentially induce tumor cell damage, promote antigen exposure, and support T cell expansion, thereby enhancing therapeutic efficacy and reducing toxic side effects. Monitoring the dynamic changes of TCR repertoire and ctDNA does not only offer insights into the mechanism underlying our therapeutic approach to some extent but also furnishes valuable data for monitoring treatment efficacy. **Materials and Methods** Study design and participants

38 Patients with resectable stage IIA to IIIA NSCLC, as per the staging criteria outlined by the American Joint Committee on Cancer, 8th edition, and possessing adequate organ function, along with an Eastern Cooperative Oncology Group performance-status rating of 0 to 1, were included in this study. All patients had not received any prior cancer treatment, exhibited measurable disease according to the Response Evaluation Criteria in Solid Tumors (version 1.1) and had confirmed histological or cytological evidence of the disease. Exclusion criteria included the presence of identified EGFR mutations or ALK translocations; a diagnosis of malignancies beyond NSCLC within 5 years; previous exposure to specific therapies such as anti-PD-1, anti-PD-L1, or anti-PD-L2 agents or medications targeting T cell receptor modulation (e.g., CTLA-4, LAG-3, or TIM-3); a history of allogeneic organ hematopoietic stem cell transplantation (except corneal transplantation); ongoing repercussions from prior interventions; pregnancy or breastfeeding; and HIV positivity. Moreover, the availability of pre- and post-adjuvant treatment tumor tissues and serial blood samples facilitated comprehensive analyses including whole transcriptome sequencing, TCR sequencing, and ctDNA sequencing.

Trial design and treatment

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

143

144

- This study was a single-center, single-arm, pilot clinical trial (Registration Number:
- 135 ChiCTR2000033092). Eligible patients aged from 45 to 72 received 2 cycles of
- 136 neoadjuvant therapy of low-dose platinum-based chemotherapy:
- albumin-bound paclitaxel 180-220 mg/m² plus cisplatin 60 mg/m² for lung squamous
- cell carcinoma or pemetrexed disodium 500 mg/m² plus cisplatin 60 mg/m² for lung
- adenocarcinoma respectively on day 1 plus sintilimab 200 mg on day 5 of each cycle,
- followed by radiographic evaluation before undergoing radical surgery. Surgery was
- 141 conducted within 6 weeks after the completion of neoadjuvant treatment. Then
- patients would receive 2 cycles of adjuvant therapy with the same regimen.

Study outcomes

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

The primary endpoints include objective response rate (ORR: the proportion of patients with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors) and major pathologic response (MPR) (less than 10% residual viable tumor cells in the primary tumor and sampled lymph nodes) according to the pathologist review. Secondary endpoint included pathologic complete response (pCR) (0% residual viable tumor cells in the primary tumor and sampled lymph nodes), disease free survival (DFS), treatment-related adverse events (TRAEs), occurrence of surgical complications, and intraoperative and perioperative complications. Plasma collection, cell-free DNA extraction, and sequencing Blood samples were collected into cell-free DNA blood streck tubes. Isolated plasma and paired white blood cell (WBC) control were stored at -80 until extraction. Cell-free DNA (cfDNA) and WBC-derived DNA were extracted from 4 mL plasma

and WBC using QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany)

and Mag-Bind® Blood & Tissue DNA HDQ 96 kit (OMEGA) according to the

manufacturer's instructions, respectively. DNA extracts were sheared to 100 bp

fragments using an S220 focused ultrasonicator (Covaris, Woodbrun, MA, USA). The

adaptors (NadPrep®) were attached to the terminal of fragments and followed by

PCR (Bio-Rad T100, USA) replication. The libraries were constructed using NadPrep

Plasma Cell-Free DNA Dual-Ended Molecular Tag Library Construction Kit (for MGI)

(Nanodigmbio). The target customized probes YuceOne Plus (ctDNA) synthesized by

IDT were used for hybridization enrichment. Target enrichment was performed with

NadPrep Hybrid Capture Reagents (Nanodigmbio). The enriched DNA fragments

were sequenced with the MGISEQ platform. The mean depth of coverage was 3445×

for cfDNA and 1419× for matched peripheral blood samples.

Circulating tumor DNA (ctDNA) analysis

SOAPnuke was implemented to cut the adapter and remove low-quality raw reads

(20). Genecore was performed for cluster reads by unique molecule index (UMI) and remove the replicated reads derived from PCR (21). Clean reads were aligned against the human reference genome (hg19) with BWA (v0.7.12) (22) and duplicated reads were removed by samtools (v0.1.19) (23). Subsequently, generated BAM files were used for downstream analysis. We compared the ctDNA samples and matched control blood sequencing data to identify the somatic mutations, including single nucleotide variants (SNVs) and small insertions and deletions (Indels) using mutation caller Vardict (v1.7.0) with default parameters (24). Next, the caller was run with dbSNP (version 147), 1000G (phase3_release_v5), CLINVAR (version 151 ClinVar (nih.gov)), and COSMIC (version 81) data for known polymorphic sites. Substitutions and indels would be filtered out according to the following criteria: 1) low variant allelic fractions (VAF < 0.0005), 2) removed any variants with greater than 1 supporting read in the matched germline sample, 3) variants present in the above genome database. In addition, the filtered mutations were annotated by snpEff (v4.3) (25) with NCBIrefseq (https://www.ncbi.nlm.nih.gov/refseq/). The maximum VAF is considered as the tumor burden during the therapy.

Whole transcriptome sequencing

- 192 The total RNA of tumor samples was isolated using the RNeasy FFPE Kit (Qiagen,
- 193 GER) according to the manufacturer's instructions. The concentrations of RNA were
- 194 quantified using Qubit™ RNA HS Assay Kit (ThermoFisher Scientific, USA). RNA
- 195 purity and integrity were checked using the Take3 (BioTek, USA) and the RNA
- 196 Cartridge kit of the Qseq100 Bio-Fragment Analyzer (Bioptic, CHN), respectively.
- 197 Then, RNA sequencing (RNA-seq) libraries were constructed using the rRNA
- depletion module (H/M/R) and NadPrep DNA Library Preparation Module for MGI
- 199 (MGI, CHN). The libraries were sequenced on the MGISEQ-T7 platform with 100 bp
- 200 paired-end reads.

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

201

202

RNA-Seq raw data quality control, gene expression analysis, and immune cell

abundance estimation

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

Raw sequencing data (raw reads) from MGISEQ-T7 was processed to filter out low-quality reads. Clean reads from each sample were aligned against the hg19 reference by STAR (v2.7.8) (26). The read counts and transcripts per million (TPM) values were calculated based on aligned RNA sequencing reads to reference transcripts downloaded from gencode (v27lift37) database, as implemented in rsem (v1.3.0) (27). Based on the gene expression matrix, R packages xCell (28) and web tool ImmunCellAI (29) were used to estimate the infiltration abundance of immune cells for each sample.

T cell receptor sequencing and analysis

For T cell receptor (TCR) sequencing, total RNA was isolated from peripheral blood mononuclear cells (PBMCs) by RNeasy Plus Mini Kit (Qiagen, USA) according to the manufacturer's instructions. QubitTM RNA HS Assay Kit (ThermoFisher Scientific, USA) was applied to determine the final concentration. Then TCR β-chain of CDR3 was amplified by Multi-IR Library Prep Kit (iGeneTech, CHN). Sequencing procedures were utilized by the MGISEQ-T7 platform with 100-bp paired-end reads. Fastq reads were trimmed based on their low-quality 3' ends to base. Trimmed pair-end reads were integrated according to overlapping alignment with the modified Needleman-Wunsch algorithm. MiXCR (v2.1.10) (30) was performed to identify the CDR3 sequences of V-D-J gene segments with reference sequences from the IMGT (31). VDJtools (v1.2.1) (32) was utilized to assess the immune repertoire sequencing. A frequency-based correction was performed on samples. The diversity of the TCR repertoire was calculated with the Shannon-Wiener index formula $H = -\sum_{i=0}^n \rho_i \ln p_i$ represents the frequency of clonotype i for the sample with n unique clonotypes. The evenness of the TCR repertoire was calculated with the formula $\frac{H}{\ln(s)}$, where H was Shannon Weiner index and S was the total number of species in a sample, across all samples in the dataset. Clonality is defined as a

normalized Shannon index over n unique clones: clonality = 1 - H/ln(n). The D50 index was also performed to evaluate the diversity according to the top 50% of the total TCR clones in the samples. According to clonotype abundance, TCR clonotypes were defined as large clones when their frequency > 0.001. Based on the frequency ranking, the top 20 most frequent TCR clones and large clones are defined as the predominant TCR clones.

Statistical analysis

All statistical analyses were implemented by R 4.0 software or SPSS 27.0. Medians and inter quartile range (IQRs) were provided for distributions of observation duration and time intervals. Wilcoxon's Rank-Sum test was used to compare across independent groups. Wilcoxon's Signed-Rank test was used for the pairwise comparison samples. All reported *P* values are two-sided, and *P* values less than 0.05 were considered statistically significant.

Results

Overview of the patient cohort

From May 2020 to November 2023, 50 patients diagnosed with NSCLC at stage IIA-IIIA were screened for eligibility, of which 38 received two cycles of modified neoadjuvant chemo-immunotherapy (**Fig. 1A**). Each cycle featured two phases, corresponding to chemotherapy and immunotherapy (**Fig. 1B**). Following modified neoadjuvant chemo-immunotherapy, 31 patients underwent R0 resection (**Figure 1A** and **Table S1**). The postoperative tissues were subjected to pathological evaluation. Samples from a representative patient (P2) who achieved pCR after neoadjuvant treatment exhibited morphological alterations, characterized by extracellular mucin pools and fibrosis (**Fig. 1C**). Computed tomography scans demonstrated the obliteration of lung lesions following neoadjuvant therapy (**Fig. 1D**). 74.2% (27/31) participants received the modified adjuvant chemo-immunotherapy (from time-point T4 to T8) (**Fig. 1A and B; Table S1**). Detailed treatment regimens are provided in

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

Table S2. Most patients were men (78.7%) and had a smoking history (81.6%). The median age of patients was 64 years (range: 37-77). All patients had ECOG performance status of 0 or 1. Baseline patient characteristics are summarized in Table 1 and detailed in Table S1. Clinical efficacy and safety After neoadjuvant therapy, 39.5% (15/38) patients achieved radiological downstaging (Fig. 2A; Table 2). The ratio of patients with CR, PR, and stable disease (SD) was 5.3% (2/38), 68.4% (26/38), and 26.3% (10/38), respectively, yielding an ORR of 73.7% (28/38) (**Fig. 2B**). 91.3% (21 of 23) were recurrence-free (**Fig. 2C**). The median interval between the last dose of sintilimab and surgery was 33 days (interquartile ranges (IQRs) 5.55 days) (Table S1). 47.4% (18/38) patients achieved a MPR and 31.6% (12/38) patients achieved a pCR (**Fig. 2D**). For patients receiving adjuvant therapy, the median interval between the surgery and the adjuvant therapy was 32.1 days (IQRs 7.2 days) (Table S1). Up to January 18, 2024, the median follow-up was 14.37 months (IQRs 24.22 months) (**Table S1**). The median OS and DFS are not reached (Fig. 2E). 44.7% (17/38) patients experienced at least one TRAE (Table 3). Grade 3 TRAEs occurred only in one patient. The most common grade 1 or 2 TRAEs were nausea (15.8%). Previously unreported toxic effects were not observed, and there were no instances of discontinuation of modified neoadjuvant chemo-immunotherapy due to toxicity. Low-dose chemotherapy combined with delayed immunotherapy has a positive effect on T lymphocytes To investigate whether dynamic changes in peripheral blood TCR repertoire were associated with treatment efficiency during modified chemo-immunotherapy, 49

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

peripheral blood samples were collected from serial time-points and evaluated using TCR sequencing (Fig. 3A). Since the predominant number of TCR clones is an important indicator of immune response and treatment efficacy (15, 33-35), the frequency of the top 20 TCR clones was analyzed at each treatment phase. Significant increase of top 20 TCR clones were observed in phase 1 to 3 (all P < 0.0001; Fig. 3B; Fig. S1). An overall increase of top 20 frequency was observed in the first cycle of neoadjuvant therapy (C1). In contrast, no significant changes were observed during adjuvant therapy (Fig. 3C; Table S3). These results suggested that the peripheral blood-derived top 20 TCR clones were continuously increased not only during low-dose chemotherapy, but also during immunotherapy within neoadjuvant therapy. According to clonotype abundance, the TCR clones were divided into 3 clonotypes, including large (frequency > 0.001), median (0.001-0.0001), and small (< 0.0001) clones. A markedly increase of large clones was observed during neoadjuvant therapy (all P < 0.05) (Fig. 3D and E), consistent with the trend of top 20 TCR clones. No significant difference was observed in the diversity, evenness, and clonality of TCR clones across the whole treatment procedure (Fig. 3F; Fig. S2; Table S4). The changes of T lymphocytes in the tumor microenvironment across the neoadjuvant therapy were analyzed based on transcriptomic data. As shown in Figure S3, the CD4+ and CD8+ T lymphocytes tended to increase during neoadjuvant therapy. Collectively, the neoadjuvant treatment had a positive effect on T lymphocytes. Reduced tumor burden in ctDNA was observed during neoadjuvant therapy To monitor the dynamic changes of tumor burden in ctDNA during therapy, peripheral blood samples were collected at serial time-points (T0 to T7) and evaluated via ctDNA sequencing. The landscape of genomic alternations was shown in Figure 4A. Among the detected genes, TP53 (50%) was the most frequently mutated gene, followed by ARIDIA (11%), DNMT3A (11%), and PIK3CA (11%) (Fig. 4A; Table S5). Throughout the entire treatment, the maximal somatic variant allelic frequency

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

(maxVAF) of ctDNA had a declining trend, especially in PH1 (T0 to T1) with dramatically decreased (P < 0.05) (Fig. 4B; Fig. S4), indicating that low-dose chemotherapy would induce tumor cell death thus reducing tumor burden. Notably, we observed that the changes in TCR and ctDNA exhibited opposite trends during the neoadjuvant therapy (Fig.3B and 3D; Fig. 4B). Taken together, these results suggest that low-dose chemotherapy combined with delayed immunotherapy not only cause the increase of tumor antigens shed into blood but also stimulate the body's immunity to produce more tumor antigen-specific T lymphocytes. **Discussion** In recent clinical trials, the combination of neoadjuvant chemotherapy with immunotherapy by administering them concurrently in patients with resectable NSCLC has brought about longer event-free survival (6, 8, 36). Although chemotherapy promotes tumor cell death and T lymphocyte infiltration (17, 18), it may also have negative effects on T lymphocyte proliferation (37). Consequently, the combination of chemotherapy with immunotherapy has been a topic of controversy. Therefore, the optimal dose, timing of administration, and sequence of therapy need urgent investigation. Our previous findings from both in vitro experiments and clinical trials have suggested that administering PD-1/PD-L1 inhibitors at 1-10 days (especially 3-5 days) after chemotherapy in lung cancer patients may be more effective than administering them before or concurrently (14). In this trial, we reported the safety and efficacy of low-dose platinum-based chemotherapy combined with delayed immunotherapy for patients with stage IIA to IIIA resectable NSCLC. After modified neoadjuvant therapy, ORR was achieved in 73.7% (28/38) of patients, which was higher than the report of CheckMate-816 (54%) (6) and comparable to those of NADIM (76%) (8) and LungMate 002 (76%) (38) trials. MPR was achieved in 47.4% (18/38) patients, with 31.6% (12/38) achieving pCR. During a median follow-up of 14.37 months, 91.3%

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

(21/23) patients were recurrence-free. These results indicated that modified neoadjuvant chemo-immunotherapy was effective in patients with resectable NSCLC. Only 2.6% (1/38) patients experienced serious TRAEs after receiving modified neoadjuvant treatment, which is lower than the rates reported in CheckMate 816 (33.5%), NAMID (30.0%) (8), and LungMate 002 (6.0%) (38) trials. The reduction of chemotherapeutics may contribute to the low incidence of serious TRAEs. Additionally, we did not observe treatment discontinuation due to toxicity. These results provide evidences that low-dose platinum-based chemotherapy combined with delayed immunotherapy as a neoadjuvant therapy is safe and less toxic.

Previous research has illustrated an association between clinical benefit and TCR repertoire as well as ctDNA level at baseline (39, 40). However, the dynamic changes in the TCR repertoire and ctDNA level during neoadjuvant treatment have been less studied. In our study, we found that the predominant TCR clones were greatly increased after the treatment of chemotherapy from phase 1 to 3, indicating that low-dose platinum-based chemotherapy did not inhibit the proliferation of predominant T cell clones which create a beneficial microenvironment for subsequent immunotherapy. Moreover, ICI treatment significantly increased the number of predominant TCR clones during neoadjuvant therapy, suggesting that immunotherapy has a positive impact on TCR clones, consistent with the study by Forde et al (41). During adjuvant therapy, no significant fluctuation in the predominant TCR clones was observed, probably because the tumor lesions were cleared. Under such circumstances, no tumor antigen was released, thus no tumor antigen-specific T cells were proliferated. Similarly, no significant change was observed in evenness or clonality of TCR. MaxVAF of ctDNA was dramatically dropped during phase 1, which is accordance with previous studies (42-44). Notably, the maxVAF of ctDNA and predominant TCR clones showed opposite trends of change in phase 1. Moreover, the maxVAF of ctDNA was close to 0 during adjuvant therapy stage.

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

Our study had several limitations that need to be acknowledged. First, it was a pilot study with a relatively small cohort and lacked a control arm. Therefore, validation of our findings in larger cohorts is necessary. Second, the follow-up period was short, and longer-term results are needed to investigate whether modified therapy provides long-term survival benefits. Finally, innovative techniques should be incorporated to further explore the underlying mechanisms of superior clinical efficacy and reduced TRAEs. In this study, the modified neoadjuvant low-dose platinum-based chemotherapy combined with delayed immunotherapy in patients with resectable NSCLC exhibited promising efficacy and feasibility. The multi-omics analyses provide the dynamic trajectories of the TCR repertoire and tumor burden, which can aim in better understanding the mechanisms of superior efficiency and the feasibility of modified chemo-immunotherapy. In the future, it is possible to conduct large-scale clinical research using this modified chemo-immunotherapy. Acknowledgements We would like to thank Innovent Biologics, Inc for providing sintilimab for this study. **Author's contributions** C.Y. Liang: Conceptualization, Formal analysis, Methodology, Writing - original draft. Q. Song: Formal analysis, Methodology, Funding acquisition, Writing - original draft. W.H. Zhou and N. Li: Formal analysis, Methodology, Writing - original draft. C.H. Pan, Q. Xiong B. Yang, and X.L Zhang: Formal analysis. S.H Zhao, W.W. Shi, X. Yan, J.T. Guo, S.J. Sun, Z.H. Dong, and Y.P. Long: Validation, Writing - reviewing & editing. B. Yang, J. Li, Y. Hu, and H.T. Luo: Conceptualization, Investigation, Validation, Verification of underlying data, Supervision, Writing - reviewing & editing.

405 **Funding**

408

409

415

416

421

424

427

- 406 This study was supported by the National Natural Science Fund of the People's
- 407 Republic of China (NSFC) No.81902912.

Data availability statement

- 410 All the analysis data can be found in the supplementary tables. The dataset supporting
- 411 the conclusions of this article is available in the Genome Sequence Archive for
- 412 Human (GSA-H) repository with accession number (HRA002904) and can be
- 413 accessed thru the URL (BIG Search National Genomics Data Center BIG Search
- 414 (cncb.ac.cn)) after reasonable request.

Declarations

417 Ethics approval and consent to participate

- 418 Ethics committee/IRB of General Hospital of the People's Liberation Army gave
- ethical approval (S2020-144-01) and written informed consent was obtained from all
- 420 participants.

422 Consent for publication

423 Not applicable.

425 Competing interests

426 The authors declare no conflicts of interest.

428 References

- 1. Liang Y, Wakelee HA. Adjuvant chemotherapy of completely resected early stage
- 430 non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2013;2(5):403-10.
- 431 2. Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl
- 432 Lung Cancer Res. 2014;3(4):242-9.
- 433 3. Taylor MD, Nagji AS, Bhamidipati CM, Theodosakis N, Kozower BD, Lau CL,

- 434 et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann
- 435 Thorac Surg. 2012;93(6):1813-20; discussion 20-1.
- 436 4. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE,
- et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM
- 438 Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for
- 439 Lung Cancer. J Thorac Oncol. 2016;11(1):39-51.
- 440 5. Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a
- 441 systematic review and meta-analysis of individual participant data.
- 442 Lancet.383(9928):1561-71.
- 443 6. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al.
- 444 Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J
- 445 Med. 2022.
- 7. Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, et
- al. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients
- 448 With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase
- 449 II Trial. J Clin Oncol. 2021;39(26):2872-80.
- 450 8. Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M,
- 451 et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung
- 452 cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. The Lancet
- 453 Oncology. 2020;21(11):1413-22.
- 454 9. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al.
- 455 Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. The New
- 456 England journal of medicine. 386(21):1973-85.
- 457 10. Gangopadhyay A, Nath P, Biswas J. Reduced Dose Intensity of Chemotherapy
- 458 may not Lead to Inferior Palliation in Locally Advanced Carcinoma of the Gall
- 459 Bladder: An Experience from a Regional Cancer Centre in Eastern India. J
- 460 Gastrointest Cancer. 2015;46(3):297-300.
- 461 11. Zhang L, Lu S, Cheng Y, Hu Z, Wu YL, Chen Z, et al. Docetaxel maintenance
- 462 therapy versus best supportive care after first-line chemotherapy with different dose

- docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study,
- 464 CTONG-0904): an open-label, randomized, phase III trial. Ann Transl Med.
- 465 2021;9(4):338.
- 466 12. Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y, et al. Reduced-dose
- 467 post-transplant cyclophosphamide plus low-dose post-trans plant anti-thymocyte
- 468 globulin as graft-versus-host disease prophylaxis with
- fludarabine-busulfan-cytarabine conditioning in haploidentical p eripheral blood stem
- 470 cell transplantation: A multicentre, randomized c ontrolled clinical trial. Br J
- 471 Haematol.200(2):210-21.
- 472 13. Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LO, et al.
- 473 Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose
- 474 monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer
- 475 (NORDIC9): a randomised, open-label phase 2 trial. Lancet Gastroenterol Hepatol.
- 476 2019;4(5):376-88.
- 477 14. Yao W, Zhao X, Gong Y, Zhang M, Zhang L, Wu Q, et al. Impact of the
- 478 combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in
- patients with refractory lung cancer. ESMO Open. 2021;6(2):100094.
- 480 15. Kidman J, Principe N, Watson M, Lassmann T, Holt RA, Nowak AK, et al.
- 481 Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint
- Therapy Responses. Front Immunol. 2020;11:587014.
- 483 16. Hellmann MD, Nabet BY, Rizvi H, Chaudhuri AA, Wells DK, Dunphy MPS, et al.
- 484 Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term
- 485 Response to PD-(L)1 Blockade in NSCLC. Clin Cancer Res. 2020;26(12):2849-58.
- 486 17. Gaudreau P-O, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, et al.
- Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident M emory T
- 488 Cell, and B Cell Infiltration in Resectable NSCLC. Journal of thoracic oncology:
- 489 official publication of the Internation al Association for the Study of Lung
- 490 Cancer.16(1):127-39.
- 491 18. Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F, et al. Cancer-cell-secreted

- 492 CXCL11 promoted CD8⁺ T cells infiltrat ion through docetaxel-induced-release of
- 493 HMGB1 in NSCLC. Journal for immunotherapy of cancer.7(1):42.
- 494 19. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for
- 495 cancer immunotherapy. Science (New York, NY).367(6477):eaax0182.
- 496 20. Chen Y, Chen Y, Shi C, Huang Z, Zhang Y, Li S, et al. SOAPnuke: a MapReduce
- 497 acceleration-supported software for integrated quality control and preprocessing of
- 498 high-throughput sequencing data. (2047-217X (Electronic)).
- 499 21. Chen S, Zhou Y, Chen Y, Huang T, Liao W, Xu Y, et al. Gencore: an efficient tool
- 500 to generate consensus reads for error suppressing and duplicate removing of NGS data.
- 501 BMC Bioinformatics. 2019;20(23):606.
- 502 22. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler
- 503 transform. (1367-4811 (Electronic)).
- 504 23. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve
- years of SAMtools and BCFtools. LID 10.1093/gigascience/giab008 [doi] LID -
- 506 giab008. (2047-217X (Electronic)).
- 507 24. Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al.
- VarDict: a novel and versatile variant caller for next-generation sequ encing in cancer
- research. Nucleic acids research.44(11):e108.
- 510 25. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for
- annotating and predicting the effects of single nucleoti de polymorphisms, SnpEff:
- 512 SNPs in the genome of Drosophila melanogaste r strain w1118; iso-2; iso-3. Fly
- 513 (Austin).6(2):80-92.
- 26. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR:
- 515 ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
- 516 27. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data
- with or without a reference genome. BMC Bioinformatics. 2011;12:323.
- 518 28. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular
- 519 heterogeneity landscape. Genome Biology. 2017;18(1):220.
- 520 29. Miao Y-R, Zhang Q, Lei Q, Luo M, Xie G-Y, Wang H, et al. ImmuCellAI: A

- 521 Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its
- 522 Application in Cancer Immunotherapy. Adv Sci (Weinh).7(7):1902880.
- 523 30. Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva
- 524 EV, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nature
- 525 Methods. 2015;12(5):380-1.
- 526 31. Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE.
- 527 IPD-IMGT/HLA Database. (1362-4962 (Electronic)).
- 528 32. Shugay M, Bagaev DV, Turchaninova MA, Bolotin DA, Britanova OV,
- Putintseva EV, et al. VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires.
- 530 PLoS Comput Biol. 2015;11(11):e1004503.
- 531 33. Zhang J, Ji Z, Caushi JX, El Asmar M, Anagnostou V, Cottrell TR, et al.
- 532 Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic
- Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.
- 534 Clin Cancer Res. 2020;26(6):1327-37.
- 535 34. Ji S, Li J, Chang L, Zhao C, Jia R, Tan Z, et al. Peripheral blood T-cell receptor
- 536 repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated
- 537 with PD-1 inhibitor. Clin Transl Oncol. 2021;23(8):1646-56.
- 538 35. Li Y, Wang J, Wu L, Li X, Zhang X, Zhang G, et al. Diversity of Dominant
- 539 Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins
- 540 Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor
- Treatment in Advanced Cancers. Front Immunol. 2021;12:649343.
- 542 36. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny
- Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
- The New England journal of medicine.381(21):2020-31.
- 545 37. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks,
- consequences, and new directions for its management. Cancer. 2004;100(2):228-37.
- 547 38. Zhu X, Sun L, Song N, He W, Xie B, Hu J, et al. Safety and effectiveness of
- 548 neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC
- 549 (LungMate 002): an open-label, single-arm, phase 2 trial. BMC Med. 2022;20(1):493.

- 39. van der Leest P, Hiddinga B, Miedema A, Aguirre Azpurua ML, Rifaela N, Ter
- Elst A, et al. Circulating tumor DNA as a biomarker for monitoring early treatment
- 552 responses of patients with advanced lung adenocarcinoma receiving immune
- 553 checkpoint inhibitors. Mol Oncol. 2021;15(11):2910-22.
- 554 40. Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Garcia Campelo MDR,
- 555 Lazaro M, et al. Pretreatment Tissue TCR Repertoire Evenness Is Associated with
- 556 Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant
- 557 Chemoimmunotherapy. Clin Cancer Res. 2021;27(21):5878-90.
- 558 41. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al.
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med.
- 560 2018;378(21):1976-86.
- 42. Jiang T, Jiang L, Dong X, Gu K, Pan Y, Shi Q, et al. Utilization of circulating
- 562 cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous
- 563 cell carcinoma. Theranostics.11(1):257-67.
- 43. Provencio M, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal
- 565 Rubio J, et al. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab
- 566 Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM
- 567 phase II trial). Journal of clinical oncology: official journal of the American Societ y
- of Clinical Oncology.40(25):2924-33.

574

575

576

- 569 44. Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab Plus
- 570 Carboplatin and Paclitaxel as First-Line Treatment f or Advanced Squamous NSCLC
- 571 (CameL-Sq): A Phase 3 Trial. Journal of thoracic oncology: official publication of the
- Internation al Association for the Study of Lung Cancer.17(4):544-57.

Table 1 Baseline clinical characteristics of patients.

Characteristics	Overall (n=38)
	overam (n=eo)

Median age (range), years	64 (37-77)
Sex, n (%)	
Male	28 (78.7%)
Female	10 (26.3%)
ECOG performance status, n (%)	
0	8 (21.1%)
1	30 (78.9%)
Histological type, n (%)	
Squamous cell carcinoma	21 (55.3%)
Adenocarcinoma	17 (44.7%)
TNM stage, n (%)	
IIA	3 (7.9%)
IIB	12 (31.6%)
IIIA	23 (60.5%)
Smoking status, n (%)	
Yes	31 (81.6%)
No	7 (18.4%)
PD-L1 TPS, n (%)	
< 1%	17 (44.7%)
1-49%	13 (34.2%)
≥ 50%	8 (21.1%)

578 Data are presented as median (range) or n (%). Abbreviations: ECOG, Eastern Cooperative

Oncology Group; TNM, tumor-nodes-metastasis; TPS, tumor proportion score.

580

Table 2 Response to modified neoadjuvant chemo-immunotherapy

Response to Treatment	Rate (%), Patient No.
Tumor down-staging rate	39.5% (15/38)
R0 resection rate	81.6% (31/38)
ORR	73.7% (28/38)

pCR rate	31.6% (12/38)
MPR rate	47.4% (18/38)

Data are presented as n%. ORR, objective response rate; pCR, pathologic complete response;

MPR, major pathological response.

583

584

Table 3 Summary of treatment-related adverse events

Table 3 Summary of treatment-related adverse events				
Treatment-related adverse	Grade 1 or 2	Grade 3		
events				
n (%)	16 (42.1%)	1 (2.6%)		
Nausea	6 (15.8%)	0		
Constipation	3 (7.9%)	0		
Decreased appetite	3 (7.9%)	0		
Anemia	2 (5.3%)	0		
Fever	2 (13.0%)	0		
Rash	2 (5.3%)	0		
Decreased neutrophil count	2 (5.3%)	0		
Diarrhea/colitis	1 (2.3%)	0		
Hepatotoxicity	1 (2.6%)	1 (2.6%)		
Hypothyroidism	1 (2.6%)	0		
Adrenal insufficiency	1 (2.6%)	0		
Hyperthyroidism	1 (2.6%)	0		
Maculopapular	0	0		
Hypersensitivity	0	0		
Pneumonitis	0	0		
Hypophysitis	0	0		
thyroiditis	0	0		
Diabetes mellitus	0	0		
Neutropenia	0	0		

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

Figure Legends Fig.1 Overview of study design and representative images. (A) Flow diagram of the study. (B) Trial schema of the study. Patients with NSCLC received modified neoadjuvant chemo-immunotherapy, followed by surgical resection and modified adjuvant chemo-immunotherapy. Tumor tissues were collected at baseline and the surgery phase. Serial blood samples were collected at baseline and each time-point for TCR and ctDNA sequencing. (C) Representative hematoxylin and eosin staining of tumor specimens obtained from patient 2 (P2), who obtained pCR. (**D**) Representative computed tomographic imaging of lung lesions of P2. NSCLC, non-small cell lung cancer; TCR, T-cell receptor; ctDNA, circulating tumor DNA; pCR, pathologic complete response. Fig.2 Clinical efficacy of modified neoadjuvant chemo-immunotherapy. (A) Tumor size changes from baseline based on radiological imaging. (B) Ring diagram showed the rate of overall response according to RECIST criteria (CR, PR, and SD) in patients. (C) Swimmer plot of 31 patients who underwent R0 resection involved in this trial. (D) Barplot showed the number of patients distributed in pathological response (pCR in blue, MPR in green, and non-MPR in red, respectively). (E) DFS curve for patients with modified treatment. CR, complete response; PR, partial response; SD, stable disease; pCR, completed pathological response; MPR, major pathological response; DFS, disease free survival. Fig. 3 Dynamic changes in T cell repertoire during therapy. (A) The schematic of samples collection and analyses performed for each patient. Top boxes represent therapeutic phases, blue for chemotherapy, yellow for immunotherapy, and purple for operation. TCR sequencing is indicated as circle. Square and triangle represents ctDNA and RNA sequencing, respectively. Solid shapes are defined as available data, while open shapes are defined as unavailable

- 616 data. (B) Comparison of top 20 TCR clones at different therapeutic phases. (C) 617 Comparison of top 20 TCR clones at different therapeutic cycles. For boxplots, each 618 box indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal 619 line represents the median; the upper whisker is the min[max(x), Q3 + 1.5 \times IQR], 620 and the lower whisker is the max[min(x), Q1 - 1.5 \times IQR], where x represents the data, 621 Q3 is the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. (D) 622 Comparison of large TCR clones at different therapeutic phases. (E) Comparison of 623 large TCR clones at different therapeutic cycles. Average and SD are shown. Wilcoxon's Signed-Rank test was used for comparison in B-E (*p < 0.05, **p < 0.01, 624 ***p < 0.001, **** p < 0.0001). (F) Changes in diversity (Shannon index) of TCR 625 clones for each patient. TCR, T-cell receptor; ctDNA, circulating tumor DNA; IQR, 626 627 interquartile range. 628 629 Fig.4 Characterization of ctDNA and the alteration of tumor burden during 630 treatment. 631 (A) Genomic landscape of mutations detected in plasma via ctDNA sequencing. 632 Frequency of mutated genes were shown on the bar of middle and the proportion was 633 shown in numerical form. Counts of mutations for each sample were displayed on top 634 bar. Frequency for each of the six substitutions of the bases spectrum was shown on 635 right. The scale lines below show the proportion of various mutation substitutions. (B) 636 Changes in maxVAF across the entire course of therapy. Wilcoxon's Signed-Rank test 637 was used for comparison. (*p < 0.05). ctDNA, circulating tumor DNA; maxVAF, 638 maximal somatic variant allelic frequency. 639 640 **Supplementary materials** 641 Fig. S1 Dynamic change of top 20 TCR clones in the distinct phases. 642 (A) Changes of top 20 TCR clones of P1, P2, P3, P10, P11, and P12 in T0 to T1 (PH

- 643 1). (B) Changes of top 20 TCR clones of P1, P2, P5, P10, P11, and P12 in T1 to T2
- (PH 2). (C) Changes of top 20 TCR clones of P2, P4, P10, P11, and P12 in T2 to T3 644

- 645 (PH 3). For boxplots, each box indicates the first quartile (Q1) and third quartile (Q3),
- and the black horizontal line represents the median; the upper whisker is the
- $\min[\max(x), Q3 + 1.5 \times IQR]$, and the lower whisker is the $\max[\min(x), Q1 1.5 \times$
- 648 IQR], where x represents the data, Q3 is the 75th percentile, Q1 is the 25th percentile,
- and IQR = Q3 Q1. Wilcoxon's Signed-Rank test was used for comparison (*p <
- 650 0.05, **p < 0.01, ***p < 0.001, **** p < 0.0001). TCR, T-cell receptor; IQR,
- 651 interquartile range.

653

657

668

Fig. S2 Characterization of temporal dynamics of the T cell repertoire in the

- 654 **longitudinal blood.**
- 655 (A) Changes of the D50 index among patients. (B) Changes of Pielou index (evenness)
- among patients. (C) Changes of clonality index among patients.

658 Fig. S3 Infiltration of CD4+ and CD8+ T lymphocytes after modified

- 659 **neoadjuvant therapy.**
- 660 (A) Relative proportion of lymphocytes was assessed by ImmunCellAI. (B) Relative
- proportion of lymphocytes was assessed by xCell. For boxplots, each box indicates
- the first quartile (Q1) and third quartile (Q3), and the black horizontal line represents
- the median; the upper whisker is the min[max(x), Q3 + 1.5 \times IQR], and the lower
- whisker is the max[min(x), Q1 1.5 \times IQR], where x represents the data, Q3 is the
- 665 75th percentile, Q1 is the 25th percentile, and IQR = Q3 Q1. Wilcoxon's
- 666 Signed-Rank test was used for comparison. Tcm, central memory T cells; Tem,
- Effector memory T cells; IQR, interquartile range.
- 669 Fig. S4 Change in maxVAF across different phases. For boxplots, each box
- 670 indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal line
- represents the median; the upper whisker is the min[max(x), O3 + 1.5 \times IOR], and the
- lower whisker is the max[min(x), Q1 1.5 \times IQR], where x represents the data, Q3 is

the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. Wilcoxon's
Signed-Rank test was used for comparison. IQR, interquartile range.

Table S1. Clinical characteristics of patients
Table S2. List of treatment regimens

Table S3. List of top 20 TCR clones frequency across the whole modified therapy
Table S4. TCR characteristics across the whole modified therapy

Table S5. Annotation of ctDNA somatic mutations







